Yesterday, a six-person jury concluded that Roundup was a substantial cause of plaintiff’s non-Hodgkins lymphoma. The verdict sends a clear message to Bayer, the company that purchased Monsanto, and for the 11,000 plaintiffs in cases already filed in courts around the country – there is a link between glyphosate and cancer. Because of the case’s national importance, the jury’s recent decision will affect many Illinois toxic tort plaintiffs, as well as those across the country.
According to a recent news report covering the trial, the case involves a man who claimed that use of the defendant’s weed-killer, Round-Up, caused him to develop non-Hodgkin’s lymphoma (NHL). Evidently, the plaintiff used the weed-killer over 300 times in his 26-year career. The plaintiff also claims that the manufacturer attempted to influence scientists, regulators, and the general public regarding the safety of the product.
The case is important for several reasons. First, it is only the second case in which jurors have had to determine whether the chemical composition in Round-Up is a substantial factor in causing NHL. The defendant manufacturer claims that its product is safe for human use, regardless of exposure levels. However, the plaintiff argues numerous studies contradict the manufacturer’s assertions, showing that the risk of developing cancer increases with the level of exposure to the product. The only previous case involved a successful claim by a California man who recovered $289 million earlier last year.